SELLAS Life Sciences Group, Inc.
Business
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company developing novel cancer therapeutics. Its lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy targeting the WT1 antigen in hematologic and solid tumors, currently in Phase 3 for acute myeloid leukemia; its secondary candidate is SLS009 (tambiciclib), a CDK9 inhibitor. The company retains development and commercialization rights outside Greater China, where it has licensed GPS to 3D Medicines.
Summary from 10-K filed 2026-03-19
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 16 | 19 | 24 | 20 | 16 | |
| General and administrative | 12 | 12 | 14 | 13 | 11 | |
| Total operating expenses | 28 | 32 | 38 | 43 | 33 | |
| Loss from operations | −28 | −32 | −38 | −42 | −25 | |
| Interest income | 1 | 632,000 | 525,000 | — | — | |
| Total non-operating income | 1 | 632,000 | 529,000 | 649,000 | 4 | |
| Net loss | −27 | −31 | −37 | −41 | −21 | |
| Net loss per common share, basic (in dollars per share) | −0.25 | −0.5 | −1.34 | −2.13 | −1.34 | |
| Net loss per common share, diluted (in dollars per share) | −0.25 | −0.5 | −1.34 | −2.13 | −1.34 | |
| Weighted-average common shares outstanding, basic (in shares) | 109 | 61 | 28 | 19 | 15 | |
| Weighted-average common shares outstanding, diluted (in shares) | 109 | 61 | 28 | 19 | 15 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-09-30 | FY 2024 2024-12-31 | FY 2024 2024-09-30 | FY 2023 2023-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 72 | — | 14 | — | 3 | |
| Restricted cash and cash equivalents | 100,000 | — | 100,000 | — | 100,000 | |
| Prepaid expenses and other current assets | 3 | — | 2 | — | 542,000 | |
| Total current assets | 75 | — | 16 | — | 3 | |
| Operating lease right-of-use assets | 963,000 | 500,000 | 925,000 | 500,000 | 858,000 | |
| Goodwill | 2 | — | 2 | — | 2 | |
| Deposits and other assets | 257,000 | — | 266,000 | — | 275,000 | |
| Total assets | 78 | — | 19 | — | 6 | |
| Accounts payable | 3 | — | 4 | — | 6 | |
| Accrued expenses and other current liabilities | 4 | — | 5 | — | 8 | |
| Operating lease liabilities | 544,000 | — | 544,000 | — | 446,000 | |
| Total current liabilities | 7 | — | 10 | — | 14 | |
| Operating lease liabilities, non-current | 457,000 | — | 457,000 | — | 460,000 | |
| Total liabilities | 7 | — | 10 | — | 14 | |
| Commitments and contingencies (Note 6) | — | — | — | — | — | |
| Common stock, $0.0001 par value; 350,000,000 shares authorized, 153,103,459 and 73,977,459 shares issued and outstanding at December 31, 2025 and 2024, respectively | 15,000 | — | 7,000 | — | 3,000 | |
| Additional paid-in capital | 346 | — | 258 | — | 209 | |
| Accumulated deficit | −275 | — | −248 | — | −217 | |
| Total stockholders equity | 71 | — | 9 | — | −8 | |
| Total liabilities and stockholders equity | 78 | — | 19 | — | 6 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Non-cash stock-based compensation | 2 | 2 | 2 | 2 | 1 | |
| Non-cash lease expense | 597,000 | 561,000 | 495,000 | 457,000 | — | |
| Prepaid expenses and other assets | −968,000 | −2 | 113,000 | 1 | −1 | |
| Accounts payable | −535,000 | −2 | 2 | 1 | −3 | |
| Accrued expenses and other current liabilities | −2 | −2 | 1 | 4 | 727,000 | |
| Operating lease liabilities | −635,000 | −533,000 | −518,000 | −471,000 | −183,000 | |
| Net cash used in operating activities | −28 | −35 | −31 | −24 | −26 | |
| Proceeds from warrant inducements, net of issuance costs | 51 | 0 | — | — | — | |
| Proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs | 23 | 46 | — | — | — | |
| Proceeds from the exercise of common stock warrants and pre-funded warrants | 13 | 560,000 | 14,000 | 0 | 3 | |
| Proceeds from employee stock plan purchases | 112,000 | 98,000 | 107,000 | 85,000 | 0 | |
| Tax withholding on vesting of restricted stock units | −527,000 | −64,000 | −31,000 | 0 | — | |
| Net cash provided by financing activities | 86 | 47 | 22 | 24 | 12 | |
| Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents | 58 | 11 | −15 | −4 | −14 | |
| Cash received during the year for interest | 1 | 632,000 | 525,000 | 317,000 | 6,000 | |
| Fair value of common stock warrants issued in warrant inducements | 67 | 0 | — | — | — | |
| Warrant modifications recorded in stockholders' equity | 0 | 725,000 | 0 | — | — | |
| Increase in operating lease right of use assets and current and non-current operating lease liabilities | 526,000 | 526,000 | 368,000 | 449,000 | 0 | |
| Offering costs in accounts payable and accrued expenses | 17,000 | 0 | 103,000 | 0 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is SELLAS Life Sciences Group, Inc.'s CIK number?
SELLAS Life Sciences Group, Inc.'s SEC CIK number is 0001390478 (1390478). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find SELLAS Life Sciences Group, Inc.'s SEC filings?
All of SELLAS Life Sciences Group, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did SELLAS Life Sciences Group, Inc. last report earnings?
SELLAS Life Sciences Group, Inc. (SLS) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001390478-26-000009). This is SELLAS Life Sciences Group, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is SELLAS Life Sciences Group, Inc.'s most recent earnings 8-K?
SELLAS Life Sciences Group, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001390478-26-000009. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View SELLAS Life Sciences Group, Inc.'s latest earnings 8-K →
Look up any company's CIK number →